NSCLC: No Overall Survival Difference Between Afatinib and Gefitinib

Share this content:
No significant difference in overall survival between afatinib and gefitinib among patients with EGFR-mutant advanced non-small cell lung cancer.
No significant difference in overall survival between afatinib and gefitinib among patients with EGFR-mutant advanced non-small cell lung cancer.

Despite significant improvements in progression-free survival and overall response rate with afatinib, there was no significant difference in overall survival between afatinib and gefitinib among patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC), according to a study published in Annals of Oncology.1

The open-label, phase 2b LUX-Lung 7 (ClinicalTrials.gov Identifier: NCT01466660) enrolled 319 treatment-naïve patients with EGFR mutation-positive stage IIIB or IV adenocarcinoma of the lung. Participants were randomly assigned 1:1 to receive first-line afatinib or gefitinib orally once daily until disease progression or unacceptable toxicity.

Previously reported results showed that afatinib significantly prolonged progression-free survival, time-to-treatment failure, and objective response rate compared with gefitinib. Investigators confirmed these results with longer follow-up.

Median follow-up was 42.6 months. There was no significant difference in overall survival between the 2 treatment arms (hazard ratio [HR], 0.86; 95% CI, 0.66-1.12; P = .2580). Median overall survival was 27.9 months with afatinib and 24.5 months with gefitinib.

Subgroup analyses revealed similar overall survival trends in patients with exon 19 deletion (HR, 0.83; 95% CI, 0.58-1.17; P = .2841) and those with L858R mutations (HR, 0.91; 95% CI, 0.62-1.36; P = .6585).

About three-quarters of patients in both groups had at least 1 subsequent systemic therapy for NSCLC after discontinuation of afatinib or gefitinib, including approximately 14% to 15% who received a third-generation EGFR kinase inhibitor such as osimertinib.

RELATED: NSCLC: Etoposide/Cisplatin May Be Superior to Carboplatin/Paclitaxel With Radiation

Although there was no significant difference in overall survival between afatinib and gefitinib, the LUX-Lung 7 trial continued to demonstrate significant improvements in other clinical outcomes with afatinib. Clinicians may use these data to inform clinical decision-making in this patient population.

Reference

  1. Paz-Ares L, Tan EH, O'Byrne K, et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. 2017 Feb 7. doi: 10.1093/annonc/mdw611 [Epub ahead of print]
Loading links....

Related Resources

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters